# GHK-Cu: Research Overview — Peptide Medicine NY > A literature summary of GHK-Cu (copper tripeptide-1), the copper-binding tripeptide studied for collagen synthesis, wound repair, and hair growth. Covers mechanism, clinical trial data, and safety cautions. A copper-binding tripeptide the body already produces — extensively studied as a cosmetic ingredient for skin and hair, and barely studied at all once it is injected instead of applied. ## The short version GHK-Cu is short for **Glycyl-L-Histidyl-L-Lysine Copper(II)** — three amino acids (glycine, histidine, lysine) locked onto a copper ion. The sequence occurs naturally in the body, inside type I collagen and a protein called SPARC, and blood levels of it fall steadily with age. Cosmetically, it is sold as "copper peptide" or "copper tripeptide-1," and it has a genuinely long track record in that form. What it has actually been shown to do: stimulate skin cells to make more collagen and elastin, help regulate the enzymes that break matrix tissue down, and — in a few small human trials — measurably improve wrinkle depth, hair count, and wound markers [1][3][4]. What it has not been shown to do: work safely or predictably as an injectable. Almost all of the strong human evidence here is topical. This page keeps those two things separate. ## What it is GHK-Cu is a linear tripeptide — glycine, histidine, lysine — chelated 1:1 to a copper(II) ion through the histidine imidazole nitrogen, the glycine amino nitrogen, and a deprotonated amide nitrogen between the two, leaving the lysine side chain free to interact with tissue. Its molecular formula is C14H23CuN6O4+, a cationic complex. The plain GHK sequence — without copper — occurs naturally within the alpha-2(I) chain of human type I collagen and in the matrix protein SPARC/osteonectin, which is part of why researchers treat it as a genuine repair signal rather than a foreign molecule. Most of the reported biological activity depends on the copper actually being bound; free GHK without copper does not reproduce several of the key effects seen in cell studies. ## How it works GHK-Cu works two ways at once: as a signaling molecule and as a copper delivery vehicle. At very low concentrations, it directly stimulates dermal fibroblasts — the cells that build skin's structural matrix — to produce more collagen, elastin, glycosaminoglycans, and decorin, while nudging the balance of matrix-remodeling enzymes against their natural inhibitors, the combination needed for tissue to actually rebuild rather than just accumulate scar-like matrix. The copper half of the molecule matters mechanistically too: it enables an enzyme called lysyl oxidase to cross-link newly made collagen and elastin fibers, and it gives the complex antioxidant, superoxide-dismutase-like activity. At the gene level, one analysis found GHK shifts expression of roughly 2,100 human genes at a 50%-or-greater threshold — mostly toward wound-repair, DNA-repair, antioxidant, and protein-quality-control pathways, and away from inflammatory NF-kB signaling [2]. ## What the research shows *Topical anti-aging efficacy.* A 2025 review found topical GHK-Cu increased procollagen synthesis in 70% of treated subjects, compared with 50% for vitamin C and 40% for retinoic acid in the same body of literature — while flagging poor skin penetration as the central formulation problem the field is still working on [1]. *Hair growth.* In a 6-month, placebo-controlled trial of 45 men with androgenetic alopecia, a topical combination of 5-aminolevulinic acid and the GHK peptide increased hair count by 52.6–71.5 hairs depending on concentration, versus 9.6 for placebo (p<0.05), with no adverse events reported in any group [3]. *Skin regeneration, broadly.* A widely cited review documents GHK-Cu stimulating collagen, dermatan sulfate, chondroitin sulfate, and decorin synthesis, alongside the observation that plasma GHK levels fall from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4]. *Delivery.* A human skin-penetration study found copper delivered as GHK-Cu penetrates dermatomed skin at a measurable rate, with a meaningful fraction retained in the dermis as a depot after 48 hours [5]. *Gene expression.* Connectivity Map analysis attributes roughly a third of all measurable gene-expression change to GHK exposure at the highest confidence threshold, concentrated in repair and antioxidant pathways [2]. Notably absent from all of this: human pharmacokinetic data for injected or systemic GHK-Cu. It does not exist yet. ## Reported effects, cautions & safety People in skincare and peptide communities describe a fairly consistent topical experience — these accounts are **anecdotal, not clinical evidence**, gathered from skincare forums, brand review pages, and community guides, not from controlled studies. *Reported benefits:* firmer, more elastic-feeling skin after several weeks of consistent use; softer fine lines over one to three months; earlier improvements in hydration and plumpness; smoother texture; and, for scalp use, less shedding and thicker-feeling hair over three to six months. A smaller group describes injecting GHK-Cu for research purposes and reports vague skin or recovery benefits — those accounts have no validated human data behind them at all. *Reported downsides:* irritation, redness, and dryness are the most common complaint, usually tied to starting at too high a concentration; some acne-prone users describe a temporary "purging" breakout phase; a minority describe skin looking duller rather than better; and layering copper peptides with vitamin C or strong acids is widely reported to cancel out both products. *What the literature actually flags as a caution:* human evidence is mostly small topical trials from a limited set of research groups, so broad anti-aging claims outrun the controlled data [1][4]. Injectable and systemic use has no human pharmacokinetic basis at all — the rat data that exists shows the free peptide breaks down quickly in blood, which does not answer basic questions about dose, frequency, or safety margin in humans. Combining GHK-Cu with vitamin C or low-pH acids in the same skincare step is a documented formulation-stability problem, not just a rumor [1]. ## Where it fits in Research Peptide Fundamentals GHK-Cu is the odd one out on this desk, and that is the point: it is the only member here whose primary evidence is topical and cosmetic rather than systemic and metabolic or neurological. Where [PT-141](/pt-141), [retatrutide](/retatrutide), and [semaglutide](/semaglutide) all work by activating specific receptors after entering the bloodstream, GHK-Cu's best-documented job happens at the skin surface, in the dermis. Reading it next to the other three is useful precisely because it shows how differently "research peptide" evidence quality can vary by route of administration — strong data for one use, essentially none for another. See the [full comparison](/compare). --- This is a literature review from an editorial desk, not a clinic, a pharmacy, or a substitute for talking to a licensed prescriber.